AVXT News Alert Avax Techs Inc (AVXT) 0.0100 09/29/2014 04:4
Post# of 273249
Posted On: 09/29/2014 5:43:55 AM
Avax Techs Inc (AVXT) 0.0100 $AVXT
AVAX Technologies Announces Expansion of Clinical Study with Autologous Ovarian Cancer Vaccine (OVax(R))
Business Wire - Tue Feb 11, 9:17AM CST
AVAX Technologies, Inc. (other OTC: "AVXT"
today announces it has expanded its ongoing Phase 1/2 study ("Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients with relapsed Stage III or IV Ovarian Cancer" to include all five Cancer Treatment Centers of America(R) (CTCA) regional hospitals. In addition, clinical data from the study was selected to be presented at the Society of Gynecologic Oncology ("SGO" 19th Annual Winter Meeting February 20 - 22, 2014 at Breckenridge, Colorado. The SGO is the premier medical specialty society for health care professionals trained in the comprehensive management of gynecologic cancers.
Global Tissue Engineering and Cell Therapy Market 2011-2015 with Advanced Cell Technology Inc. and Medtronic Inc. Dominating
M2 - Wed Jan 16, 6:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/2q5bhp/global_tissue) has announced the addition of the "Global Tissue Engineering and Cell Therapy Market 2011-2015" report to their offering. TechNavio's analysts forecast the Global Tissue Engineering and Cell Therapy market to grow at a CAGR of 18 percent over the period 2011-2015. One of the key factors contributing to this market growth is the significant advancements in RandD. The Global Tissue Engineering and Cell Therapy market has also been witnessing an increase in mergers and acquisitions. However, stringent regulatory requirements could pose a challenge to the growth of this market. The key vendors dominating this market space are Baxter International Inc., DePuy Inc., Medtronic Inc., Stryker Corp., and Zimmer Holdings Inc. The other vendors mentioned in the report are 3DM Inc., Aastrom Biosciences Inc., Acorda Therapeutics Inc., Advanced BioHealing Inc., Advanced Cell Technology Inc., Advanced Medical Solutions Group plc, Aeol
AVAX Technologies Announces Expansion of Clinical Study with Autologous Ovarian Cancer Vaccine (OVax(R))
Business Wire - Tue Feb 11, 9:17AM CST
AVAX Technologies, Inc. (other OTC: "AVXT"
today announces it has expanded its ongoing Phase 1/2 study ("Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients with relapsed Stage III or IV Ovarian Cancer" to include all five Cancer Treatment Centers of America(R) (CTCA) regional hospitals. In addition, clinical data from the study was selected to be presented at the Society of Gynecologic Oncology ("SGO" 19th Annual Winter Meeting February 20 - 22, 2014 at Breckenridge, Colorado. The SGO is the premier medical specialty society for health care professionals trained in the comprehensive management of gynecologic cancers. Global Tissue Engineering and Cell Therapy Market 2011-2015 with Advanced Cell Technology Inc. and Medtronic Inc. Dominating
M2 - Wed Jan 16, 6:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/2q5bhp/global_tissue) has announced the addition of the "Global Tissue Engineering and Cell Therapy Market 2011-2015" report to their offering. TechNavio's analysts forecast the Global Tissue Engineering and Cell Therapy market to grow at a CAGR of 18 percent over the period 2011-2015. One of the key factors contributing to this market growth is the significant advancements in RandD. The Global Tissue Engineering and Cell Therapy market has also been witnessing an increase in mergers and acquisitions. However, stringent regulatory requirements could pose a challenge to the growth of this market. The key vendors dominating this market space are Baxter International Inc., DePuy Inc., Medtronic Inc., Stryker Corp., and Zimmer Holdings Inc. The other vendors mentioned in the report are 3DM Inc., Aastrom Biosciences Inc., Acorda Therapeutics Inc., Advanced BioHealing Inc., Advanced Cell Technology Inc., Advanced Medical Solutions Group plc, Aeol
(0)
(0)Scroll down for more posts ▼